Immunocore Holdings Ltd (NASDAQ:IMCR) — Market Cap & Net Worth
Market Cap & Net Worth: Immunocore Holdings Ltd (IMCR)
Immunocore Holdings Ltd (NASDAQ:IMCR) has a market capitalization of $1.42 Billion ($1.42 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7598 globally and #2154 in its home market, demonstrating a -3.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunocore Holdings Ltd's stock price $28.16 by its total outstanding shares 50530419 (50.53 Million). Analyse IMCR cash generation efficiency to see how efficiently the company converts income to cash.
Immunocore Holdings Ltd Market Cap History: 2021 to 2026
Immunocore Holdings Ltd's market capitalization history from 2021 to 2026. Data shows change from $1.73 Billion to $1.42 Billion (-7.85% CAGR).
Index Memberships
Immunocore Holdings Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.06% | #203 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #800 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.09% | #127 of 263 |
Weight: Immunocore Holdings Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunocore Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunocore Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.02x
Immunocore Holdings Ltd's market cap is 6.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.73 Billion | $36.48 Million | -$180.03 Million | 47.42x | N/A |
| 2022 | $2.88 Billion | $144.23 Million | -$43.46 Million | 19.99x | N/A |
| 2023 | $3.45 Billion | $249.43 Million | -$55.29 Million | 13.84x | N/A |
| 2024 | $1.49 Billion | $247.77 Million | -$40.81 Million | 6.02x | N/A |
Competitor Companies of IMCR by Market Capitalization
Companies near Immunocore Holdings Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Immunocore Holdings Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Immunocore Holdings Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Immunocore Holdings Ltd's market cap moved from $1.73 Billion to $ 1.42 Billion, with a yearly change of -7.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.42 Billion | -18.87% |
| 2025 | $1.75 Billion | +17.66% |
| 2024 | $1.49 Billion | -56.82% |
| 2023 | $3.45 Billion | +19.71% |
| 2022 | $2.88 Billion | +66.68% |
| 2021 | $1.73 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Immunocore Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.42 Billion USD |
| MoneyControl | $1.42 Billion USD |
| MarketWatch | $1.42 Billion USD |
| marketcap.company | $1.42 Billion USD |
| Reuters | $1.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more